GE HealthCare GEHC recently announced a strategic collaboration with Erasmus MC University Medical Center to evaluate next-generation total body PET/CT technology, marking a major stride in precision imaging and cancer care. The partnership aims to advance early disease detection, personalized treatment planning, and outcome monitoring through ultra-sensitive imaging capabilities and AI-driven workflow innovations.
The initiative underscores GE HealthCare’s leadership in molecular imaging and commitment to enabling precision care. By integrating advanced PET/CT technology into clinical research, the collaboration is expected to accelerate breakthroughs in oncology and theranostics, helping clinicians detect, stage, and treat diseases with greater speed, clarity, and confidence.
Following the announcement, the company’s shares traded flat until yesterday’s closing. Shares have lost 5.1% in the year-to-date period against the industry’s 5.3% growth. The S&P 500 has gained 15.6% in the same time frame.
This partnership is poised to strengthen GE HealthCare’s market position in the fast-growing molecular imaging segment by showcasing the clinical potential of its next-generation PET/CT technology. Collaborating with a leading research institution like Erasmus MC enhances GEHC’s credibility, accelerates product validation and opens doors for broader adoption across hospitals and cancer centers globally. In turn, it supports long-term revenue growth through expanded PET/CT system sales, advanced software solutions and service contracts tied to precision oncology and theranostic applications.
GEHC currently has a market capitalization of $34.3 billion. It has an earnings yield of 6.03%, higher than the industry’s 0.09%. In the last reported quarter, GEHC delivered an earnings surprise of 16.5%.
Zacks Investment Research
Image Source: Zacks Investment Research
GE HealthCare’s collaboration with Erasmus MC represents a significant step in its ongoing efforts to transform precision care through advanced molecular imaging. The two organizations will jointly evaluate GEHC’s next-generation total body PET/CT technology, which features a 128 cm axial field of view designed for ultra-low dose scans, faster image acquisition and multi-organ dynamic imaging. This innovation aims to enhance diagnostic accuracy and workflow efficiency, especially in oncology and theranostic applications where precise imaging is critical for early detection and treatment planning. By integrating deep learning-based technologies, the platform also supports improved image quality and operational efficiency, key value drivers for healthcare systems looking to optimize patient throughput and resource utilization.
For GE HealthCare, this collaboration not only reinforces its technological leadership in the PET/CT space but also strengthens its clinical credibility through direct engagement with one of Europe’s most advanced medical research centers. Erasmus MC’s proven expertise in theranostics, including its pioneering work in developing and implementing treatments such as Lu-177-Dotatate, provides an ideal environment for testing and refining GEHC’s total body PET/CT technology.
The partnership will explore protocol optimization, dose reduction, and dynamic imaging capabilities, with an emphasis on translating research innovations into scalable clinical solutions. This research-driven validation can help GEHC accelerate regulatory approvals and drive adoption among hospitals seeking next-generation imaging systems for oncology care.
In addition to advancing technology development, the partnership underscores GEHC’s strategy to grow its footprint in the precision medicine and molecular imaging markets. The company’s existing ecosystem, which includes products like the Omni Legend PET/CT system, SIGNA PET/MR, and StarGuide SPECT/CT, already positions it strongly in imaging innovation. Through this collaboration, GEHC gains deeper insights into clinical needs and real-world performance data that can inform future product enhancements and strengthen its competitive edge.
Per a report by Grand View Research, the global cancer diagnostics market size was estimated at $109.61 billion in 2024 and is projected to reach $155.07 billion by 2030, with a CAGR of 6.14% from 2025 to 2030.
Growth of the cancer diagnostics market is attributed to the growing prevalence of cancer, technological advancements in diagnostics procedures and rising initiatives undertaken by private & public organizations.
Currently, GEHC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Masimo MASI, Merit Medical System MMSI and West Pharmaceutical Services WST. Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Masimo shares have lost 10.4% so far this year compared with the industry’s 7.4% decline. Estimates for the company’s 2025 earnings per share have increased 1.3% to $5.30 in the past 30 days.
MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Merit Medical’s 2025 earnings per share have increased 0.8% to $3.63 in the past 60 days. Shares of the company have lost 13.8% so far this year against the industry’s 1.1% growth.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.92%. In the last reported quarter, it delivered an earnings surprise of 17.44%.
Estimates for West Pharmaceutical’s 2025 earnings per share have increased 1.2% to $6.74 in the past 60 days. Shares of the company have lost 18.2% so far this year against the industry’s 1% growth.
WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.81%. In the last reported quarter, it delivered an earnings surprise of 21.85%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
